Fringe Opening sequence (Season 3 – Entrada) – Video

Posted on by


Fringe Opening sequence (Season 3 - Entrada)
The show #39;s standard opening sequence interplays images of the glyph symbols alongside words representing fringe science topics, such as "teleportation" and "dark matter". Within the third season, with episodes that took place primarily in the parallel universe, a new set of titles was used, following a similar format, though tinted red instead of blue and using alternate fringe science concepts like "hypnosis" and "neuroscience". The difference in color has led some fans to call the prime universe the Blue one in contrast to the parallel Red one. In the third season episode "Entrada", the titles used a mix of both the blue- and red-tinted versions, given the episode taking place equally in both universes. In the show #39;s two flashback episodes, "Peter" and "Subject 13", a variation on the sequence, using retro graphics akin to 1980s technology and phrases like "personal computing" and "genetic engineering", was used. For the dystopian future third season episode "The Day We Died", a black-toned theme, with more dire phrases like "hope" and "water," was used. The fourth season premiere, "Neither Here Nor There" introduced an amber-toned title sequence with additional new terms that is used for nearly all season four episodes. The fourth season episode "Letters of Transit", which returned to the future dystopian universe, and the subsequent fifth season episodes, feature a cold-toned title sequence with phrases such as "joy", "private thought" and "free will", ideas which ...From:Fdor Nicola MisuriViews:0 0ratingsTime:00:36More inMusic

Originally posted here:

Fringe Opening sequence (Season 3 - Entrada) - Video

Fringe Opening sequence (Season 3 – Olivia) – Video

Posted on by


Fringe Opening sequence (Season 3 - Olivia)
The show #39;s standard opening sequence interplays images of the glyph symbols alongside words representing fringe science topics, such as "teleportation" and "dark matter". Within the third season, with episodes that took place primarily in the parallel universe, a new set of titles was used, following a similar format, though tinted red instead of blue and using alternate fringe science concepts like "hypnosis" and "neuroscience". The difference in color has led some fans to call the prime universe the Blue one in contrast to the parallel Red one. In the third season episode "Entrada", the titles used a mix of both the blue- and red-tinted versions, given the episode taking place equally in both universes. In the show #39;s two flashback episodes, "Peter" and "Subject 13", a variation on the sequence, using retro graphics akin to 1980s technology and phrases like "personal computing" and "genetic engineering", was used. For the dystopian future third season episode "The Day We Died", a black-toned theme, with more dire phrases like "hope" and "water," was used. The fourth season premiere, "Neither Here Nor There" introduced an amber-toned title sequence with additional new terms that is used for nearly all season four episodes. The fourth season episode "Letters of Transit", which returned to the future dystopian universe, and the subsequent fifth season episodes, feature a cold-toned title sequence with phrases such as "joy", "private thought" and "free will", ideas which ...From:Fdor Nicola MisuriViews:3 0ratingsTime:00:36More inMusic

Read the rest here:

Fringe Opening sequence (Season 3 - Olivia) - Video

Fringe Opening sequence (Season 3 – The Day We Died) – Video

Posted on by


Fringe Opening sequence (Season 3 - The Day We Died)
The show #39;s standard opening sequence interplays images of the glyph symbols alongside words representing fringe science topics, such as "teleportation" and "dark matter". Within the third season, with episodes that took place primarily in the parallel universe, a new set of titles was used, following a similar format, though tinted red instead of blue and using alternate fringe science concepts like "hypnosis" and "neuroscience". The difference in color has led some fans to call the prime universe the Blue one in contrast to the parallel Red one. In the third season episode "Entrada", the titles used a mix of both the blue- and red-tinted versions, given the episode taking place equally in both universes. In the show #39;s two flashback episodes, "Peter" and "Subject 13", a variation on the sequence, using retro graphics akin to 1980s technology and phrases like "personal computing" and "genetic engineering", was used. For the dystopian future third season episode "The Day We Died", a black-toned theme, with more dire phrases like "hope" and "water," was used. The fourth season premiere, "Neither Here Nor There" introduced an amber-toned title sequence with additional new terms that is used for nearly all season four episodes. The fourth season episode "Letters of Transit", which returned to the future dystopian universe, and the subsequent fifth season episodes, feature a cold-toned title sequence with phrases such as "joy", "private thought" and "free will", ideas which ...From:Fdor Nicola MisuriViews:0 0ratingsTime:00:36More inMusic

Original post:

Fringe Opening sequence (Season 3 - The Day We Died) - Video

Vascular Complications In Human Disease – Video

Posted on by


Vascular Complications In Human Disease
ll4.me Vascular Complications In Human Disease Therapy for Pulmonary Vascular Disease.- Nitric Oxide Axis in Cardio-Pulmonary Disease.- Endothelin Signalling in the Cardiomyocyte.- TGF-beta/BMP Signalling in Pulmonary Vascular Disease.- The Endothelin System in Chronic Kidney Disease.- Endothelial Activation in Inflammation.- Pathogenic Mediators of Vessel Sclerosis.- Control of Interstitial Fluid Homeostasis.- Vascular Complications of Systemic Sclerosis.- Therapeutic Options for Preventing Transplant-Related Progressive Renal and Vascular Injury.- Current State of Medical Therapies for Peripheral Vascular Disease.- Advantages of Harvesting the Saphenous Vein for Coronary Artery Bypass Surgery Using the "No- Touch" Technique.- Towards the Prevention of Vein Graft Failure.- Statins and Cholesterol.- Endothelin-1 Promoting Actions in the Growth and Angiogenesis of Solid Cancers.- Gene Therapy for Apolipoprotein AI and HDL The Ultimate Treatment for Atherosclerosis?- Ets Family of Transcription Factors and Vascular System.- The Aortic Valve: From Function to Tissue Engineering. EAN/ISBN : 9781846289194 Publisher(s): Springer, Berlin, Springer, London Discussed keywords: Gef (Medizin) Format: ePub/PDF Author(s): Abraham, David - Dashwood, Michael - Handler, Clive Therapy for Pulmonary Vascular Disease.- Nitric Oxide Axis in Cardio-Pulmonary Disease.- Endothelin Signalling in the Cardiomyocyte.- TGF-beta/BMP Signalling in Pulmonary Vascular Disease.- The EndothFrom:aidarader985Views:0 0ratingsTime:00:14More inPeople Blogs

View original post here:

Vascular Complications In Human Disease - Video

Europe approves therapy to fix bad genes that will cost $1.6M per patient

Posted on by

LONDON, Nov 2 (Reuters) - European officials have approved the Western world's first gene therapy drug from a small Dutch biotech company, in a milestone for the novel medical technology that fixes faulty genes.

The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros ($1.6 million) per patient, a new record for pricey modern medicines.

After more than 20 years of experiments and a series of disappointments, the EU approval of Glybera, which treats the genetic disorder lipoprotein lipase deficiency (LPLD), is a significant boost for the gene therapy field.

Joern Aldag, chief executive of Amsterdam-based uniQure, said more such treatments would follow and argued a high price was justified because gene therapy restored natural body function and did not just offer a short-term fix.

"This provides higher benefit to patients than the classical protein replacement strategy and this is why we think we should be fairly and adequately compensated," he said in a telephone interview on Friday.

Patients with LPLD, which affects no more than one or two people per million, are unable to handle fat particles in their blood and are at risk of acute and potentially fatal inflammation of the pancreas.

The approval follows a positive recommendation from the European Medicines Agency in July.

The privately owned firm is now working with governments on potential pricing strategies, which are likely to vary from country to country, ahead of the commercial roll-out from the second half of 2013.

Aldag said some countries preferred the idea of a one-off payment at the time of treatment but others were interested in an annuity system, which would probably involve charging around 250,000 euros a year for five years.

That kind of annual charge would put Glybera in a similar price range to expensive enzyme replacement therapies for other rare diseases, such as Cerezyme for Gaucher disease from Sanofi's Genzyme unit.

More:

Europe approves therapy to fix bad genes that will cost $1.6M per patient

Europe backs first gene therapy

Posted on by

2 November 2012 Last updated at 07:00 ET By James Gallagher Health and science reporter, BBC News

A treatment which corrects errors in a person's genetic code has been approved for commercial use in Europe for the first time.

The European Commission has given Glybera marketing authorisation, meaning it can be sold throughout the EU.

It is a gene therapy for a rare disease which leaves people unable to properly digest fats.

The manufacturers say it will be available next year.

Gene therapy has a simple premise. If there is a problem with part of a patient's genetic code then change the code.

However, the field has been plagued with problems. Patients have developed leukaemia and in one trial in the US a teenager died.

In Europe and the US, the therapies are used only in research labs.

Glybera is used to treat lipoprotein lipase deficiency. One in a million people have damaged copies of a gene which is essential for breaking down fats.

It means fat builds up in the blood leading to abdominal pain and life-threatening inflammation of the pancreas (pancreatitis).

Read more:

Europe backs first gene therapy

European Union Approves New Gene Therapy Drug

Posted on by

November 2, 2012

Lee Rannals for redOrbit.com Your Universe Online

A drug that has the ability to correct errors in a genetic code has been approved for the first time ever in Europe.

The European Commission has given Glybera authorization to sell the drug next summer for treating an ultra rare genetic disease.

The small Dutch biotech companys drug will cost around $1.6 million per patient, a new record price for medicine.

The drug is a gene therapy for a rare disease that leaves people unable to properly digest fats, which affects one in a million people. As fat builds up in the blood, it leads to abdominal pain and life-threatening inflammation of the pancreas. The only way to manage the condition is with a very low-fat diet.

UniQures drug uses a virus to infect muscle cells with a working copy of the gene that breaks down fats.

Treating patients by replacing a defective gene with a working copy first came to light in 1990, when the worlds first gene therapy clinical tests against a rare condition called severe combined immunodeficiency (SCID) took place.

People who suffer from SCID are unable to cope with infections and usually die in childhood. The researchers trying to use gene therapy against the condition faced a setback in 1999 when an Arizona teenager died in a gene therapy experiment. A few years later, two French boys with SCID developed leukemia after being treated.

The Chinese firm SiBono GeneTech won approval for a gene therapy drug for head and neck cancer in 2003, but no products have been approved in the U.S. or Europe.

Go here to read the rest:

European Union Approves New Gene Therapy Drug

First gene therapy drug given European license

Posted on by

Gene therapy drug given green light for rare disease Glybera to cost 1m ($1.6m) for each patient Drug is first to get approval in Western world EU go-ahead paves way for many more treatments

By Jenny Hope

PUBLISHED: 08:19 EST, 2 November 2012 | UPDATED: 21:14 EST, 2 November 2012

Revolution: Gene therapies can change a person's DNA

Regulators yesterday approved the first therapy in the western world that can correct errors in a persons genetic code.

Europe has approved Glybera to be used against a rare inherited disorder which disrupts fat production in the body.

The treatment uses a virus to counteract LPLD, lipoprotein lipase deficiency, which can led to acute inflammation of the pancreas.

The illness affects around one or two people per million and sufferers have damaged copies of a gene which is essential for breaking down fats. The virus infects muscle cells with a copy of a healthy gene and a one-off treatment is effective.

The treatment was backed by an advisory panel to the European Commission in July and full approval was granted yesterday. The medicine should be available next year.

Professor John Kastelein, of the University of Amsterdam, said the therapy would have a dramatic impact on patients.

Go here to see the original:

First gene therapy drug given European license

UPDATE 1-Europe approves high-price gene therapy

Posted on by

* European Commission clears Glybera for ultra rare disease

* UniQure drug is first gene therapy to reach market in West

* Glybera likely to cost around $1.6 million per patient

* Final EU approval follows positive recommendation in July (Adds interview with company CEO, pricing details, background)

By Ben Hirschler

LONDON, Nov 2 (Reuters) - European officials have approved the Western world's first gene therapy drug from a small Dutch biotech company, in a milestone for the novel medical technology that fixes faulty genes.

The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros ($1.6 million) per patient, a new record for pricey modern medicines.

After more than 20 years of experiments and a series of disappointments, the EU approval of Glybera, which treats the genetic disorder lipoprotein lipase deficiency (LPLD), is a significant boost for the gene therapy field.

Joern Aldag, chief executive of Amsterdam-based uniQure, said more such treatments would follow and argued a high price was justified because gene therapy restored natural body function and did not just offer a short-term fix.

"This provides higher benefit to patients than the classical protein replacement strategy and this is why we think we should be fairly and adequately compensated," he said in a telephone interview on Friday.

The rest is here:

UPDATE 1-Europe approves high-price gene therapy

uniQure's Glybera® First Gene Therapy Approved by European Commission

Posted on by

AMSTERDAM, The Netherlands, November 2, 2012 /PRNewswire/ --

uniQure announced today it has received approval from the European Commission for the gene therapy Glybera (alipogene tiparvovec), a treatment for patients with lipoprotein lipase deficiency (LPLD, also called familial hyperchylomicronemia) suffering from recurring acute pancreatitis. Patients with LPLD, a very rare, inherited disease, are unable to metabolize the fat particles carried in their blood, which leads to inflammation of the pancreas (pancreatitis), an extremely serious, painful, and potentially lethal condition. The approval makes Glybera the first gene therapy approved by regulatory authorities in the Western world.

"Glybera's approval means LPLD patients, for the first time, have a medical treatment option for a very complex and severe disease," said Professor John Kastelein of the Department of Vascular Medicine at the Academic Medical Center of the University of Amsterdam, the Netherlands. "LPLD leads to acute and recurrent pancreatitis attacks, and in many patients causes early onset diabetes and cardiovascular complications. This therapy will have a dramatic impact on the lives of these patients. Currently their only recourse is to severely restrict the amount of fat they consume. By helping to normalize the metabolism of fat, Glybera prevents inflammation of the pancreas thereby averting the associated pain and suffering and, if administered early enough, the associated co-morbidities."

As part of the approval, patients will receive treatment with Glybera through dedicated centers of excellence and by specially trained doctors. uniQure will also build a patient registry to further improve the understanding of this devastating, under-researched disease and the effects of Glybera treatment. Marketing Authorisation covers all 27 European Union member states. uniQure is preparing to apply for regulatory approval in the US, Canada, and other markets.

"The final approval of Glybera from the EC marks a major step forward in making gene therapies available not only for LPLD but also for a large number of rare diseases with a very high unmet medical need," says Jrn Aldag, CEO of uniQure. "The EC's approval is an important validation of our innovative product platform and offers strong support for our other advanced development programs, which focus on acute intermittent porphyria, Sanfilippo B, hemophilia B and Parkinson's disease."

About Glybera

uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency, an orphan disease for which no treatment existed. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL enzyme in patients. This enzyme is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. Excess chylomicrons result in recurrent and severe acute inflammation of the pancreas, called pancreatitis, the most debilitating complication of LPLD. Glybera has orphan drug designation in the EU and US. LPL Deficiency affects 1-2 persons per million.

Glybera has been tested in three interventional clinical studies conducted in the Netherlands and in Canada, in which a total of 27 LPLD patients participated. In all three clinical trials, Glybera was well tolerated, with no relevant safety issues observed. Data from these clinical trials indicate that a single dose administration of Glybera resulted in a long-term biological activity of the LPL protein. For further information on LPLD visit http://www.lpldeficiency.com.

Lipoprotein lipase is a key 'first step' enzyme in the metabolism of lipoproteins following fat intake with diet. In clinical studies a transient reduction in triglycerides for up to 12 weeks in individual patients could be observed. Furthermore, Glybera allows expression of the LPL protein in injected muscle which is reflected by the improvement of postprandial chylomicron (CM) metabolism observed in a small subset of patients. Glybera (alipogene tiparvovec) contains the human lipoprotein lipase (LPL) gene variant LPL S447X in a vector. The vector comprises a protein shell derived from adeno-associated virus serotype 1 (AAV1), the promoter, a posttranscriptional regulatory element and AAV2 derived inverted terminal repeats.

Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.

See the original post:

uniQure's Glybera® First Gene Therapy Approved by European Commission

Europe approves high-price gene therapy

Posted on by

LONDON (Reuters) - European officials have approved the Western world's first gene therapy drug from a small Dutch biotech company, in a milestone for the novel medical technology that fixes faulty genes.

The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros ($1.6 million) per patient, a new record for pricey modern medicines.

After more than 20 years of experiments and a series of disappointments, the EU approval of Glybera, which treats the genetic disorder lipoprotein lipase deficiency (LPLD), is a significant boost for the gene therapy field.

Joern Aldag, chief executive of Amsterdam-based uniQure, said more such treatments would follow and argued a high price was justified because gene therapy restored natural body function and did not just offer a short-term fix.

"This provides higher benefit to patients than the classical protein replacement strategy and this is why we think we should be fairly and adequately compensated," he said in a telephone interview on Friday.

Patients with LPLD, which affects no more than one or two people per million, are unable to handle fat particles in their blood and are at risk of acute and potentially fatal inflammation of the pancreas.

The approval follows a positive recommendation from the European Medicines Agency in July.

The privately owned firm is now working with governments on potential pricing strategies, which are likely to vary from country to country, ahead of the commercial roll-out from the second half of 2013.

Aldag said some countries preferred the idea of a one-off payment at the time of treatment but others were interested in an annuity system, which would probably involve charging around 250,000 euros a year for five years.

That kind of annual charge would put Glybera in a similar price range to expensive enzyme replacement therapies for other rare diseases, such as Cerezyme for Gaucher disease from Sanofi's Genzyme unit.

Go here to see the original:

Europe approves high-price gene therapy

Precognition

Posted on by


Precognition Dreams
Precognition Dreams Must See! Dreams that came True! Appearing during the first three hours, author, researcher and psychotherapist Dr. Laurie Nadel discussed precognitive dreams, and how many people had dreams and visions before 9-11. The dreaming mind can pick up impressions and images of events that haven #39;t happened yet, or people who haven #39;t come into your life yet, she said. The Seneca Indians gathered once a week to discuss their dreams, but western society typically lacks a forum for sharing this kind of material, she noted. However, the Arlington Institute, a futurist think tank, does provide an online form to record precognitive or intuitive dreams. Nadel told of her first precognitive dream at age 11, in which she dreamed her family #39;s pet parakeet was lying dead in the bottom of its cage while in a car. This event actually occurred several weeks after the dream. A few months before 9-11, many people reported reoccurring dreams about planes, birds, towers, and people falling out of buildings; this was a kind of a "intensification in the collective subconscious" and people #39;s ability to perceive these symbols, she said. A precognitive dream can sometimes be differentiated from a normal dream, if a person is having a lucid dream or a strong feeling that comes with the dream, she explained. Interestingly, Nadel noted that dreams about strange and unusual cloud formations are currently being reported. The clouds are described as dark, low to the horizon, completely ...From:Angels2TouchYou2Views:0 0ratingsTime:02:34:41More inScience Technology

Original post:

Precognition

The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012 – Video

Posted on by


The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012
A fascinating inside look at the coming world of Synthetic Biology. Andrew Hessel is a futurist and catalyst in biological technologies, helping industry, academics, and authorities better understand the changes underway in life science. Trained in microbiology and genetics, Andrew has continually worked at the forefront of life science in industry and academia. He is faculty at Singularity University, where he co-chaired the Biotechnology and Bioinformatics track and now helps startup biotechnology companies organize and launch. He is also a fellow at the University of Ottawa, Institute for Science, Society, and Policy, and the founder of the world #39;s first cooperative biotechnology company, the Pink Army Cooperative, which is working to create open source therapies for cancer. Andrew has given dozens of invited talks related to synthetic biology, for groups that include Intel Inc., the FBI, and the United Nations. In thespirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)From:TEDxTalksViews:65 11ratingsTime:19:05More inScience Technology

Here is the original post:

The Dark Side of the Double Helix: Andrew Hessel at TEDx Marin 2012 - Video

Joel Kotkin: The Inevitable Burst of Social Media Bubble – Video

Posted on by


Joel Kotkin: The Inevitable Burst of Social Media Bubble
Complete program available for free at fora.tv Author and futurist Joel Kotkin expresses skepticism on the long-term viability of California #39;s social media startups. "Social media reminds me of the last dot-com boom," says Kotkin. "I #39;ve seen this movie before, and it was better the last time."From:ForaTvViews:135 11ratingsTime:03:13More inNews Politics

Go here to read the rest:

Joel Kotkin: The Inevitable Burst of Social Media Bubble - Video

From Ego to Eco: Introduction to Nov 5 2012 Event in Sao Paulo (Futurist Speaker Gerd Leonhard) – Video

Posted on by


From Ego to Eco: Introduction to Nov 5 2012 Event in Sao Paulo (Futurist Speaker Gerd Leonhard)
See the details here: gerd.fm BIG ANNOUNCEMENT to my Brazilian friends and tweeps: please join Gerd on November 5 2012 for this very promising event at the Museum of Sound in Sao Paulo, organized by Gilson Schwartz and Joe Tripician in Sao Paulo Do Ego ao Eco ao cone. Rumo ao futuro sustentvel pela economia criativa com Gerd Leonhard Dia 5 de novembro das 9h s 12 horas ao Museu da Imagem e Som, So Paulo. Participao de Davi Nakano (POLI-USP) e Gilson Schwartz (ECA-USP). Qual a relao entre economia verde, inovao tecnolgica e novas mdias. Data: Dia 5 de novembro das 9h s 12 horas Local: Museu da Imagem e Som - Avenida Europa, 158, Jardim Europa, So Paulo - SP, Brasil Informaes: iconomia.brasil@gmail.com gamesforchange.org.br Please note: You can now download most of my videos by simply subscribing to this iTunes video feed (via Blip.tv) gerd.fm *** audio-only versions are now available here: gerd.fm or on the web at http://www.futuretalks.com My vimeo channel is here vimeo.com Enjoy! Gerd Leonhard Futurist, Author and Keynote Speaker Basel / Switzerland http://www.gerdfuturist.com CEO http://www.thefuturesagency.com Media Blog http://www.mediafuturist.com Gerd #39;s mobile apps: road.ie The Future of Business blog http://www.futureof.biz Public Speaking schedule: gerd.fm Twitter: http://www.twitter.com Need even more links? about.me Category: People Blogs License: Creative Commons Attribution license (reuse allowed)From:alvairsfulViews:0 0ratingsTime:08:41More inEducation

See the original post here:

From Ego to Eco: Introduction to Nov 5 2012 Event in Sao Paulo (Futurist Speaker Gerd Leonhard) - Video

MERLIN Project, Prophecy

Posted on by


MERLIN Project, Prophecy Hidden Agendas - Coast to Coast AM Classic
http://www.jetnews.us Date: 07-07-12 Host: John B. Wells Guests: Paul Guercio, Stan Johnson In the first two hours, John B. Wells welcomed futurist Paul Guercio for an update on the MERLIN Project, a time-pattern forecasting technology he developed with Dr. George Hart. Guercio announced a new consumer product that utilizes the MERLIN forecasting software to determine the ideal period in which to sell real estate. The success rate is better than seven out of ten, even in areas where property is not moving, he said. A forthcoming MERLIN smartphone app that provides relationship timetraks is also in the works, he noted. Guercio reviewed several MERLIN timetraks (see links below) and explained what they may be predicting for the future. There is no need to worry about the world ending in December 2012. "The end of the Mayan Calendar is going to be about as interesting as Y2K," Guercio surmised. Economic difficulties will persist in the US, with continued fallout from the #39;08 financial collapse and threat of a double dip recession, he warned. Regarding the upcoming presidential election, Guercio predicted Obama will likely (70% chance) beat any other candidates, though his life may be at risk next term. Obamacare will survive, he added. On the world stage, Guercio expects a re-establishment of the former Soviet Union under Vladimir Putin, Egypt #39;s military to slowly relinquish power to the Muslim Brotherhood, and Pope Benedict XVI to possibly die (50/50 chance) this year. MERLIN ...From:C2CPlanetViews:13 0ratingsTime:02:32:01More inEducation

Link:

MERLIN Project, Prophecy

Secrets of Math Key To Higher Dimensions – Video

Posted on by


Secrets of Math Key To Higher Dimensions
Secrets of Math Author and futurist Dr. Cliff Pickover discussed his latest work, The Math Book, which explores how mathematics is the key to higher dimensions, aliens, infinity, parallel worlds, time travel, simulated realities, and Tunisian ant brains. ................................................................................................................................... Subscribe and get the Latest Show Here http://www.youtube.comFrom:Angels2TouchYou2Views:0 0ratingsTime:02:38:37More inScience Technology

Read more from the original source:

Secrets of Math Key To Higher Dimensions - Video

Futurist Joel Kotkin targets gulf coast economy that includes Tampa Bay as rising economic powerhouse

Posted on by

"While the other two coasts struggle with economic stagnation and dysfunctional politics, the Third Coast -- the urbanized, broadly coastal region spanning the Gulf from Brownsville, Texas, to greater Tampa -- is emerging as a center of industry, innovation and economic growth."

Wake up and good morning. Leave it to famed trend watcher and futurist Joel Kotkin to offer a fresh geographic and economic appraisal of the gulf coast region stretching from Texas east to Tampa Bay as a rising powerhouse.

"Over the past decade, Texas and Florida have ranked first and second among the states in net domestic immigration, combining for a gain of roughly 2 million people. Together, Houston and Tampa have gained more than 1.5 million people over the course of the decade."

Kotkin's insights appear in an interesting piece this week headlined The Third Coast in City Journal, which is part of the Wall Street Journal. Here's a link to the complete story.

Kotkin's key point is that the gulf coast is gaining population and economic power as an energy center and international shipping and trade region best situated to take advantage of doing business with Latin America. Granted, Kotkin focuses on Houston as the rising star and America's next great city, but the context of the gulf coast region, which he cites as stretching east to Tampa Bay, suggests this metro area is part of a bigger geographic and economic trend.

The article is the latest of many reminders of how important the Port of Tampa and some of the nearby secondary ports are to the larger metro area. Especially as the search is under way to find a super-sharp successor to Port chief Richard Wainio.

Kotkin's written many books on urban and economic trends. His new book, The Next Hundred Million: American in 2050, suggests the United States will continue to be a powerhouse with 400 million (versus today's 300 million) population. But running counter to much of the "smart growth" scenarios in which future growth will be built on higher density cities and less sprawl, Kotkin says the next 100 million will spread themselves across a broader, smarter and more economically independent suburban landscape.

Got to love the futurists. Read this Kotkin piece for a different slice of where Tampa Bay may fit in the economic days ahead.

Photo courtesy of Joel Kotkin.

-- Robert Trigaux, Business Columnist, Tampa Bay Times

Read more:

Futurist Joel Kotkin targets gulf coast economy that includes Tampa Bay as rising economic powerhouse

: : Access to Arasaka : : xt10.20zp9 [ music video ] – Video

Posted on by


: : Access to Arasaka : : xt10.20zp9 [ music video ]
Taking his name from the "Cyberpunk 2020 Prime; off-shoot card game "Netrunner", the once elusive Access To Arasaka has seemly come out of nowhere to take the electronic music community by storm with his debut full-length CD album #39;Oppidan #39; in 2009. A futuristic journey of a cerebral nature, demonstrating a virtual equinox of surgical beatwork and densely-layered atmospheres, #39;Oppidan #39; transcended complexity and innovation in electronic music to arrived at the very edge of its own inner space. The Rochester, NY producer #39;s cyberpunk influences are evident as he skillfully paints each sonic soundscape with expert precision and meticulous attention to detail. The artist describes his music as "a mixture of every influence I #39;ve ever had, past and present. As the general idea of this project is a way to describe the future I anticipate, the sounds and styles themselves are an homage to every song that has already taken me there." Available now is Access To Arasaka #39;s new full-length album titled #39;void(); #39; on Tympanik Audio. Sixteen fantastic new tracks of dark sonic futurism inspired by the history and future of system hacking. An open invitation for the listener to imagine what a computer might attempt to comprehend when it #39;s system is under such an attack. #39;void(); #39; is available now, only from Tympanik Audio. Download #39;void(); #39; wallpapers: Version #1 | Version #2 In 2011, Access To Arasaka and Tympanik Audio offered 2 new digital EPs titled #39;Orbitus #39; and #39;Aleph #39; for free download ...From:kernel409Views:1 0ratingsTime:05:05More inMusic

See the article here:

: : Access to Arasaka : : xt10.20zp9 [ music video ] - Video